ADVICENNE

ADVICENNE lists on Euronext

Advicenne

Advicenne, ticker symbol: ADVIC), a specialist in the research and development of drugs for the treatment of neglected neurological and nephrological diseases, began trading on Euronext Paris. 

QUOTES   |  PRESS RELEASE  WWW.ADVICENNE.COM

 

Advicenne
Listing of Advicenne on Euronext 

"Our goal is to improve the lives of patients from early childhood through adulthood by leveraging our pharmaceutical and clinical development expertise to develop pediatric friendly therapeutics that answer critical unmet medical needs in the field of rare and neglected diseases."

 

ADVICENNE

Back to previous page

Identification

ADVIC
Name: ADVICENNE
Market: Euronext Paris
Capitalization compartment: Compartment C
Subsector: Biotechnology
Isin code: FR0013296746
Symbol: ADVIC

Operation

IPO Date: 06/12/2017
Issue type: Initial Public offering
IPO Price: EUR 14.03
Price range: EUR 14.03 - EUR 18.97

Company Profile

Loading... Please wait.

News

Date Title
06 Dec 2017 Pharmaceuticals specialist Advicenne lists on Euronext Paris expand

IPO raises €27 million; market capitalisation €112 million

Paris – 6 December 2017 – Advicenne, a pharmaceutical SME from the south of France at advanced stages of development, today celebrated its first day of trading on Euronext Paris. Funds raised through listing will help the company pursue clinical development of its leading product in Europe and the United States, and finance commercial growth in Europe.

Founded in Nîmes in 2007 by Dr Luc-André Granier, MD, and Caroline Roussel-Petit, respectively Chairman & CEO and Director of Operations, Advicenne develops therapeutic products for children and adults suffering from rare renal and neurological diseases. From the start, the company has been backed by leading venture capital investors including InnoBio (Bpifrance), IXO Private Equity, IRDI Soridec Gestion, Cemag Invest and MI Care, as well as private investors.

Advicenne (ticker code ADVIC) was listed through the admission to trading on 6 December 2017 of 8,002,696 shares making up the company’s equity, including 2,007,718 new shares (after partial exercise of the extension clause and before exercise of the overallotment option), raising a total of €27 million euros, and may rise to €28.2 million euros in case of full-exercise of the over-allotment option.

The offering price was set at €14,03 per share and market capitalisation was around €112 million on the day of listing.

At the listing ceremony, the company’s co-founder, Chairman & CEO Dr. Luc-André Granier, said: “We are delighted to have completed our initial public offering on Euronext Paris, and to welcome new investors alongside our historical shareholders, who have confirmed their ongoing support for our team and our work. We would like to thank each and every one, both individuals and institutions, for placing their trust in Advicenne. This IPO represents a milestone in our strategy, and will enable us to pursue the clinical development of our lead product in both Europe and the United States, and lay the groundwork for its planned commercialisation in Europe in 2020.”

06 Dec 2017 IPO Advicenne expand

Listing of Advicenne on Euronext 

Dr. Luc-André Granier, CEO and co-founder of Advicenne, open the trading day in Paris.

Advicenne specializes in the research and development of drugs for the treatment of neglected neurological and nephrological diseases, mostly among children.